|
|
|
|
LEADER |
00000pam a22000004a 4500 |
001 |
5818979 |
003 |
ICU |
005 |
20061108123500.0 |
008 |
050412s2005 enka b 001 0 eng |
010 |
|
|
|a 2005047360
|
020 |
|
|
|a 0470866810 (alk. paper)
|
040 |
|
|
|a DNLM/DLC
|c DLC
|d DLC
|d UtOrBLW
|d OrLoB-B
|
042 |
|
|
|a pcc
|
050 |
0 |
0 |
|a RM302.5
|b .P53 2005
|
060 |
1 |
0 |
|a QZ 42
|b P536 2005
|
082 |
0 |
0 |
|a 615/.7042
|2 22
|
245 |
0 |
0 |
|a Pharmacoepidemiology /
|c edited by Brian L. Strom.
|
250 |
|
|
|a 4th ed.
|
260 |
|
|
|a Chichester ;
|a Hoboken, NJ :
|b J. Wiley,
|c c2005.
|
300 |
|
|
|a xvii, 889 p. :
|b ill. ;
|c 25 cm.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
0 |
|g 1.
|t What is pharmacoepidemiology? /
|r Brian L. Strom --
|g 2.
|t Study designs available for pharmacoepidemiology studies /
|r Brian L. Strom --
|g 3.
|t Sample size considerations for pharmacopidemiology studies /
|r Brian L. Strom --
|g 4.
|t Basic principles of clinical pharmacology relevant to pharmacoepidemiology studies /
|r David A. Henry, Patricia McGettigan, Anne Tonkin and Sean Hennessy --
|g 5.
|t When should one perform pharmacoepidemiology studies? /
|r Brian L. Strom --
|g 6.
|t A view from academia /
|r Robert M. Califf and Leanne K. Madre --
|g 7.
|t A view from industry /
|r Robert F. Reynolds, Dale B. Glasser and Gretchen S. Dieck --
|g 8.
|t A view from regulatory agencies /
|r Peter Arlett, Jane Moseley and Paul J. Seligman --
|g 9.
|t Spontaneous reporting in the United States /
|r Syed Rizwanuddin Ahmad, Roger A. Goetsch and Norman S. Marks --
|g 10.
|t Global drug surveillance : the WHO programme for international drug monitoring /
|r I. Ralph Edwards, Sten Olsson, Marie Lindquist and Bruce Hugman --
|g 11.
|t Case-control surveillance /
|r Lynn Rosenberg, Patricia F. Coogan and Julie R. Palmer --
|g 12.
|t Prescription-event monitoring /
|r Saad A. W. Shakir --
|g 13.
|t Overview of automated databases in pharmacoepidemiology /
|r Brian L. Strom --
|g 14.
|t Group health cooperative /
|r Kathleen W. Saunders, Robert L. Davis and Andy Stergachis --
|g 15.
|t Kaiser Permanente medical case program /
|r Joe V. Selby, David H. Smith, Eric S. Johnson, Marsha A. Raebel, Gary D. Friedman and Bentson H. McFarland --
|g 16.
|t The HMO research network /
|r K. Arnold Chan, Robert L. Davis, Margaret J. Gunter, Jerry H. Gurwitz, Lisa J. Herrinton, Winnie W. Nelson, Marsha A. Raebel, Douglas W. Roblin, David H. Smith and Richard Platt --
|g 17.
|t UnitedHealth Group /
|r Deborah Shatin, Nigel S. B. Rawson and Andy Stergachis --
|g 18.
|t Medicaid databases /
|r Sean Hennessy, Jeffrey L. Carson, Wayne A. Ray and Brian L. Strom --
|g 19.
|t Health services databases in Saskatchewan /
|r Winanne Downey, MaryRose Stang, Patricia Beck, William Osei and James L. Nichol --
|g 20.
|t Automated pharmacy record linkage in the Netherlands /
|r Hubert G. Leufkens and John Urquhart --
|g 21.
|t The Tayside medicines monitoring unit (MEMO) /
|r Li Wei, John Parkinson and Thomas M. MacDonald --
|g 22.
|t The UK general practice research database /
|r Joel M. Gelfand, David J. Margolis and Hassy Dattani --
|g 23.
|t Other approaches to pharmacoepidemiology studies /
|r Brian L. Strom --
|g 24.
|t How should one perform pharmacoepidemiology studies? : choosing among the available alternatives /
|r Brian L. Strom --
|g 25.
|t National medicinal drug policies : their relationship to pharmacoepidemiology /
|r Suzanne Hill and David A. Henry --
|g 26.
|t Premarketing applications of pharmacoepidemiology /
|r Harry A. Guess --
|g 27.
|t Studies of drug utilization /
|r David Lee and Ulf Bergman --
|g 28.
|t Evaluating and improving physician prescribing /
|r Sumit R. Majumdar, Helene Levens Lipton and Stephen B. Soumerai --
|g 29.
|t Drug utilization review /
|r Sean Hennessy, Stephen B. Soumerai, Helene Levens Lipton and Brian L. Strom --
|g 30.
|t Special methodological issues in pharmacoepidemiology studies of vaccine safety /
|r Robert T. Chen, Robert L. Davis and Philip H. Rhodes --
|g 31.
|t Pharmacoepidemiologic studies of devices /
|r Roselie A. Bright --
|g 32.
|t Studies of drug-induced birth defects /
|r Allen A. Mitchell --
|g 33.
|t Pharmacoepidemiology and risk management /
|r David J. Graham, Andrew D. Mosholder, Kate Gelperin and Mark I. Avigan --
|g 34.
|t The use of pharmacoepidemiology to study medication errors /
|r Rainu Kaushal and David W. Bates --
|g 35.
|t Hospital pharmacoepidemiology /
|r Brian L. Strom and Ritu Schinnar --
|g 36.
|t Determining causation from case reports /
|r Judith K. Jones --
|g 37.
|t Molecular pharmacoepidemiology /
|r Stephen E. Kimmel, Hubert G. Leujkens and Timothy R. Rehbeck --
|g 38.
|t Biothical issues in pharmacoepidemiologic research /
|r David Casarett, Jason Karlawish, Elizabeth Andrews and Arthur Caplan --
|g 39.
|t The use of randomized controlled trials for pharmacoepidemiology studies /
|r Samuel M. Lesko and Allen M. Mitchell --
|g 40.
|t The use of pharmacoepidemiology to study beneficial drug effects /
|r Brian L. Strom and Kenneth L. Melmon --
|g 41.
|t Pharmacoeconomics : economic evaluation of pharmaceuticals /
|r Kevin A. Schulman, Henry A. Glick and Daniel Polsky --
|g 42.
|t Using quality-of-life measurements in pharmacoepidemiologic research /
|r Holger Schunemann, Gordon H. Guyatt and Roman Joeschke --
|g 43.
|t N-of-1 randomized clinical trials in pharmacoepidemiology /
|r Gordon H. Guyatt, Roman Jaeschke and Robin Roberts --
|g 44.
|t The use of meta-analysis in pharmacoepidemiology /
|r Jesse A. Berlin and Carin J. Kim --
|g 45.
|t Validity of pharmacoepidemiologic drug and diagnosis data /
|r Suzanne I. West, Brian I. Strom and Charles Poole --
|g 46.
|t Variable compliance and persistence with prescribed drug dosing regimens : implications for benefits, risk, and economics of pharmacotherapy /
|r John Urquhart --
|g 47.
|t Bias and confounding in pharmacoepidemiology /
|r Ilona Csizmadi, Jean-Paul Collet and Jean-Francois Boivin --
|g 48.
|t Novel approaches to pharmacoepidemiology study design and statistical analysis /
|r Samy Suissa --
|g 49.
|t The future of pharmacoepidemiology /
|r Brian L. Strom and Sean Hennessy.
|
650 |
|
0 |
|a Pharmacoepidemiology.
|0 http://id.loc.gov/authorities/subjects/sh89004031
|
650 |
|
0 |
|a Pharmacology.
|0 http://id.loc.gov/authorities/subjects/sh85100599
|
650 |
1 |
2 |
|a Pharmacoepidemiology
|x methods.
|
650 |
|
7 |
|a Pharmacoepidemiology.
|2 fast
|0 http://id.worldcat.org/fast/fst01060242
|
650 |
|
7 |
|a Pharmacology.
|2 fast
|0 http://id.worldcat.org/fast/fst01060259
|
700 |
1 |
|
|a Strom, Brian L.
|0 http://id.loc.gov/authorities/names/n88088423
|1 http://viaf.org/viaf/41996111
|
901 |
|
|
|a ToCBNA
|
903 |
|
|
|a HeVa
|
903 |
|
|
|a Hathi
|
035 |
|
|
|a (OCoLC)59279735
|
929 |
|
|
|a cat
|
999 |
f |
f |
|i 0ff1bd87-259b-5e88-9abc-0fdaa319f308
|s 8563151b-4b75-581a-b3cd-437bac46e1d6
|
928 |
|
|
|t Library of Congress classification
|a RM302.5 .P53 2005
|l JCL
|c JCL-Sci
|i 4991453
|
927 |
|
|
|t Library of Congress classification
|a RM302.5 .P53 2005
|l JCL
|c JCL-Sci
|e CRERAR
|b 75024536
|i 7953733
|